Elizabeth Ofili
Cardiovascular Disease · Atlanta, GANPI 1275528846
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $81,548 of the $107,013 with a category attached, or 76.2%. 13 manufacturers reported payments, led by Amgen at 35.7% of the total. Reporting peaked in 2019 at $46,690 and has fallen 93.4% since, to $3,072 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $1408.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$38K
- E.r. Squibb & Sons, L.L.C.$29K
- Arbor Pharmaceuticals, Inc.$17K
- Pfizer$12K
- Alnylam Pharmaceuticals Inc.$5K
- Boehringer Ingelheim$3K
- plus $3K from 7 others
Across 10 payments — averaging $438,311 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4.4M
What the payments were for
- Consulting fees$81,54876%
- Speaking & faculty fees$17,24016%
- Travel & lodging$6,2336%
- Food & beverage$1,8322%
- Education$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $38,164 |
| E.r. Squibb & Sons, L.L.C. | 15 | $28,823 |
| Arbor Pharmaceuticals, Inc. | 12 | $16,950 |
| Pfizer | 5 | $12,204 |
| Alnylam Pharmaceuticals Inc. | 1 | $4,920 |
| Boehringer Ingelheim | 1 | $3,000 |
| Novartis | 1 | $1,925 |
| Janssen Global Services, LLC | 1 | $505 |
| Akcea Therapeutics, Inc. | 4 | $168 |
| Esperion Therapeutics, Inc. | 1 | $124 |
| THD America, Inc. | 1 | $123 |
| Merck | 2 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$107,013 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 26 | $458 |
| Metoprolol Succinate | 25 | $335 |
| Valsartan | 12 | $296 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 12 | $171 |
| Amlodipine Besylate | 17 | $8 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Atlanta
- Joseph MillerAtlanta$573K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Mani VannanAtlanta$157K
- Victor CorriganAtlanta$114K
- Isida BykuAtlanta$78K
- Cindy GrinesAtlanta$75K
- Anekwe OnwuanyiAtlanta$56K
- Melvin EcholsAtlanta$51K
- Venkateshwar PolsaniAtlanta$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.